Xiubao Ren
Overview
Explore the profile of Xiubao Ren including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
283
Citations
8359
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liu S, Ma S, Liu G, Hou L, Guan Y, Liu L, et al.
Adv Sci (Weinh)
. 2025 Feb;
:e2411053.
PMID: 40013761
Anti-PD-1 therapy has left an indelible mark in the field of non-small-cell lung cancer (NSCLC) treatment; however, its efficacy is limited in clinical practice owing to differences in the degree...
2.
Meng S, Meng Y, Yang X, Yu W, Li B, Liu T, et al.
BMC Biol
. 2025 Feb;
23(1):51.
PMID: 39985000
Background: Proteolysis targeting chimera (PROTAC), a novel drug discovery strategy, utilizes the ubiquitin-proteasome system to degrade target proteins in cells. While Western blotting, mass spectrometry, and Lumit Immunoassay have been...
3.
Zhao X, Gao X, Yu W, Lu Y, Li X, Tan L, et al.
J Vis Exp
. 2025 Feb;
(215).
PMID: 39895652
Pancreatic cancer is an aggressive malignancy with a dismal prognosis and limited therapeutic options. Adoptive cell therapy, which involves isolating and activating a patient's own immune cells, such as tumor-infiltrating...
4.
Pang B, Wang J, Zhang J, Ren X, Han Y
Transl Lung Cancer Res
. 2024 Dec;
13(11):3106-3121.
PMID: 39670021
Background: In past studies, peripheral blood D-dimer and platelets have shown predictive value in the treatment of non-small cell lung cancer (NSCLC). However, it remains unclear whether pretreatment D-dimer and...
5.
6.
Li Y, Chen Y, Meng Y, Shen M, Yang F, Ren X
Cancer Biol Med
. 2024 Dec;
21(12.
PMID: 39651787
Objective: The combination of epithelial growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and immune checkpoint inhibitors (ICIs) leads to an increased incidence of severe immune-related adverse events (irAEs). However, the...
7.
Zhou C, Chen G, Huang Y, Zhou J, Lin L, Feng J, et al.
J Immunother Cancer
. 2024 Nov;
12(11).
PMID: 39608979
Background: CameL phase 3 study demonstrated the superiority of camrelizumab plus chemotherapy over chemotherapy alone for progression-free survival in patients with previously untreated advanced non-squamous non-small-cell lung cancer (NSCLC) without...
8.
Xiong Y, Wang L, Zhang W, Meng Y, Wang Y, Shen M, et al.
BMC Cancer
. 2024 Oct;
24(1):1326.
PMID: 39472861
Background: The safety and efficacy of combination of gefitinib with chemotherapy and bevacizumab in treatment patients with epidermal growth factor receptor (EGFR) mutations are currently unknown. This study was designed...
9.
Pu J, Liu T, Sharma A, Jiang L, Wei F, Ren X, et al.
Exp Hematol Oncol
. 2024 Oct;
13(1):105.
PMID: 39468695
The basic idea of modulating the immune system to better recognize and fight tumor cells has led to the successful introduction of adoptive cellular immunotherapy (ACT). ACT-based treatment regimens, in...
10.
Shang X, Xie Y, Yu J, Zhang C, Zhao G, Liang F, et al.
Cancer Cell
. 2024 Oct;
42(10):1747-1763.e7.
PMID: 39406186
In this phase II study, 47 patients with locally advanced, resectable esophageal squamous cell carcinoma (ESCC) received three cycles of pembrolizumab plus chemotherapy, followed by Da Vinci robot-assisted surgery. The...